Using Fibroscan to guide lower anti-rejection medicine after liver transplant
Part of Immune system & allergy clinical trials.
This trial uses a special ultrasound (Fibroscan) to check your liver health and see if you can safely reduce your anti-rejection medications. It is for people who are at least 2 years past a liver transplant and whose liver is working well.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had a liver transplant at least 2 years ago
- You are 18 years or older
- No rejection episode in the last 12 months
- Your liver enzymes (ALT and bilirubin) are normal
- You did not have a transplant for an autoimmune liver disease
- You are not more than 6 years past your transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether it is safe to stop or reduce anti-rejection medicines in children who have had a liver transplant for at least 4 years and are doing well. The goal is to see if they can live without these medicines and their side effects.
This study tests a new approach to managing anti-rejection medicines after a heart transplant. It uses special blood tests to see if your immune system is calm, so doctors can safely reduce the medicines and lower side effects.
This study uses a special ultrasound (Fibroscan) to check how well immunotherapy is working for advanced liver cancer. It may help doctors see if the treatment is effective without needing a biopsy.
This study tests if some liver transplant patients can safely take lower doses of their immune-suppressing medicines, potentially reducing side effects. It uses a biomarker test to guide the treatment changes.
This study tests a new way to lower the amount of immune-suppressing medicine needed after a liver transplant. It uses special treatments before or during the transplant to help your body accept the new liver with fewer drugs, which may reduce side effects.
This trial tests whether switching from a standard anti-rejection medicine to a different one (everolimus) about a year after a liver transplant can help protect your new liver with fewer side effects. If you qualify, you will be monitored closely for a few years to see how well the new medicine works for you.
Hear when a new Immunosuppression trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.